Seegene launches CE-marked Allplex MDRO assay
May 28, 2026—Seegene launched its new antimicrobial resistance testing product, the Allplex MDRO assay.
Webinars and Sponsored Roundtables — Register Now
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Horiba launches Yumivet VH2500 hematology analyzer
May 27, 2026—Horiba has launched Yumivet, its new veterinary diagnostics brand, and introduced the Yumivet VH2500 hematology analyzer.
FujiFilm, mTuitive partner to integrate technologies
May 26, 2026—FujiFilm Healthcare Americas has announced a strategic partnership with mTuitive under which it will integrate mTuitive’s structured pathology reporting platform with FujiFilm’s Synapse Pathology picture archiving and communication system.
Grundium acquires Visiopharm, adding AI software to its scanner portfolio
May 21, 2026—Finland’s Grundium, backed by U.S.-based health care private equity firm EW Healthcare Partners, has acquired Visiopharm, of Denmark.
Anchor Molecular releases BCR-ABL1 control panels
May 20, 2026—Anchor Molecular launched its BCR-ABL1 control panels designed to support laboratories in monitoring the performance of the quantitative detection of BCR-ABL1 translocation mRNA transcripts.
Streck gets IVD clearance for MDx-Chex controls, launches blood culture tube
May 19, 2026—Streck has received in vitro diagnostic clearance for three MDx-Chex controls for sepsis testing.
FDA OK’s Signatera CDx for muscle-invasive bladder cancer
May 18, 2026—The FDA has approved Natera’s Signatera CDx as a companion diagnostic for use with adjuvant atezolizumab (Tecentriq) immunotherapy in muscle-invasive bladder cancer to identify patients who are ctDNA molecular residual disease–positive and may benefit from treatment.
PTS Diagnostics product discontinuation notice
May 13, 2026—The following customer bulletin about A1CNow+ Controls (REF 737) is published at the request of Nova-One Diagnostics.
Streck launches CD-Chex Daily flow cytometry control
May 12, 2026—Streck launched CD-Chex Daily, a ready-to-use quality control for flow cytometry laboratories.
Roche to acquire PathAI for up to $1 billion
May 7, 2026—Roche has entered into a definitive merger agreement to acquire PathAI, extending a partnership that began in 2021 and expanded in 2024 to develop AI-based companion diagnostic algorithms.